Compare Standard Lithium Ltd (SLI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Standard Lithium Ltd trades at $1.58 (market cap $398.07M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 25.4× Standard Lithium Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SLI | XBI | |
|---|---|---|
Market Cap | $398.07M | $10.11B |
Volume | 1,564,155 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $5.65 | $169.55 |
52-Week Low | $1.58 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $260.98M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.61, down 2.42% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company is pre-revenue with significant losses, reporting negative EBITDA of $50.53 million for 2025, but has made progress on its South West Arkansas lithium project, targeting a final investment decision by end of 2026. Analyst consensus is unanimously bullish with a $3.83 price target.
The investment case hinges on successful project execution and commercialization, offering substantial upside if milestones are met. Key risks include the capital-intensive nature of lithium production, execution delays, and reliance on future financing, with current cash flow sustained by financing activities.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
